𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously

✍ Scribed by F. Belardelli; I. Gresser; C. Maury; P. Duvillard; M. Prade; M.-T. Maunoury

Publisher
John Wiley and Sons
Year
1983
Tongue
French
Weight
636 KB
Volume
31
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Administration of highly purified interferon to DA/2 mice inhibited the growth of interferon‐sensitive or interferon‐resistant Friend erythroleukemia cells implanted subcutaneously. Injection of interferon at the site of tumor inoculation was more effective than injection of interferon intraperitoneally. Histologic examination of tumors in interferon‐treated mice showed extensive areas of tumor‐cell necrosis in the absence of an obvious host‐cell infiltrate. Interferon inhibited the growth of established subcutaneous tumors and induced complete tumor regression in some mice. Interferon treatment also resulted in an inhibition of tumor metastases in the liver and spleen.

📜 SIMILAR VOLUMES

Antitumor effects of interferon in mice
Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. I.
✍ F. Belardelli; I. Gresser; C. Maury; M.-T. Maunoury 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 French ⚖ 753 KB

## Abstract Interferon‐sensitive (745) and interferon‐resistant (3Cl‐8) Friend leukemia cells (FLC) are highly tumorigenic for DBA/2 mice. The phenotype of interferon sensitivity or resistance does not change with __in vivo__ passage. Daily administration of mouse interferon markedly enhanced the s

Antitumor effects of interferon in mice
Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. II. Role of host mechanisms
✍ F. Belardelli; I. Gresser; C. Maury; M.-T. Maunoury 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 French ⚖ 450 KB 👁 1 views

## Abstract We have attempted to determine what host mechanisms are responsible for inducing a rapid decrease in the number of Friend leukemia cells (FLC) in the peritoneal cavity of interferon‐treated mice. By injecting radiolabelled FLC, we showed that there was a greater loss of radioactivity fr

Anti-tumor effects of interferon in mice
Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. IV. Definition of optimal treatment regimens
✍ Ion Gresser; Filippo Belardelli; Chantal Maury; Michael G. Tovey; Marie-Thérèse 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 French ⚖ 689 KB

Mouse interferon a@? exerted a similar anti-tumor effect in DBA/2 mice injected i.p. with Friend erythroleukemia cells (FLC) either sensitive or resistant to interferon as determined by both in vitro and in vivo assays. Using this tumor system we attempted to define optimal treatment regimens for in

Anti-tumor effects of interferon in mice
Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases
✍ Ion Gresser; Chantal Maury; Claude Carnaud; Edward De Maever; Marie-Thérése Maun 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 French ⚖ 758 KB

DBAl2 mice were injected i.v. with IFN alp-resistant 3C I 8 Friend erythroleukemia cells (FLC) which metastasize to the liver and spleen. IFN d p treatment of FLC-injected mice increased their survival time and these mice developed a resistance to a second challenge with FLC. The efficacy of IFN d p

Therapeutic effects of monoclonal antibo
Therapeutic effects of monoclonal antibody g250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts
✍ J. van Dijk; H. Uemura; A. J. M. C. Beniers; W. P. Peelen; S. Th. Zegveld; G. J. 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 1015 KB

Because renal-cell carcinoma (RCC) is considered relatively resistant to radio-and chemotherapy, RCC patients may benefit from new treatment modalities, e.g. immunotherapy. In vitro and in vivo studies suggest that combinations of cytokines such as interferon y or interferon a (IFN-y, IFN-a) and tum